Drug Name: Semaglutide Manufacturer: Novo Nordisk Type: GLP-1 agonist Brand Names: Ozempic = Type 2 Diabetes, weekly injection (approved December, 2017) Rebylsus = Type 2 Diabetes, daily pill (approved September, 2019) Wegovy = Weight Loss, weekly injection (approved June, 2021) Drug Name: Tirzepatide Manufacturer: Eli Lilly Type: GLP-1/GIP co-agonist Brand Names: Mounjaro = Type 2 Diabetes, weekly injection (approved May, 2022) Zepbound = Weight Loss Application, weekly injection (approved November, 2023) (No pill form exists as of this writing) The short story is that both drugs were originally introduced as effective Type 2 Diabetes medications
The following adverse reactions are discussed elsewhere: Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates actually observed in clinical practice
This approach avoids the superfood trap and empowers consumers to build resilient dietary patterns based on sound hormetic principles
Wadden TA, Hollander P, Klein S et al (2013) Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study
